Switch theme
Sign up to access all valuation multiples
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
2016
34
LTM Revenue $8.5M
LTM EBITDA n/a
-$40.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
LAVA Therapeutics has a last 12-month revenue of $8.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, LAVA Therapeutics achieved revenue of $12.0M and an EBITDA of -$23.5M.
LAVA Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See LAVA Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $6.8M | $12.0M | XXX | XXX | XXX |
| Gross Profit | n/a | $3.3M | XXX | XXX | XXX |
| Gross Margin | NaN% | 27% | XXX | XXX | XXX |
| EBITDA | -$40.2M | -$23.5M | XXX | XXX | XXX |
| EBITDA Margin | -594% | -196% | XXX | XXX | XXX |
| Net Profit | -$31.9M | -$42.0M | XXX | XXX | XXX |
| Net Margin | -471% | -350% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, LAVA Therapeutics's stock price is $1.
LAVA Therapeutics has current market cap of $30.5M, and EV of -$40.8M.
See LAVA Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$40.8M | $30.5M | XXX | XXX | XXX | XXX | $-1.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, LAVA Therapeutics has market cap of $30.5M and EV of -$40.8M.
LAVA Therapeutics's trades at -4.8x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate LAVA Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for LAVA Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$40.8M | XXX | XXX | XXX |
| EV/Revenue | -3.4x | XXX | XXX | XXX |
| EV/EBITDA | 1.7x | XXX | XXX | XXX |
| P/E | -1.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 2.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLAVA Therapeutics's NTM/LTM revenue growth is -100%
LAVA Therapeutics's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $1.2M for the same period.
Over next 12 months, LAVA Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate LAVA Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for LAVA Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 77% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -196% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -42% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 110% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 237% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 348% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
LAVA Therapeutics acquired XXX companies to date.
Last acquisition by LAVA Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . LAVA Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was LAVA Therapeutics founded? | LAVA Therapeutics was founded in 2016. |
| Where is LAVA Therapeutics headquartered? | LAVA Therapeutics is headquartered in United States of America. |
| How many employees does LAVA Therapeutics have? | As of today, LAVA Therapeutics has 34 employees. |
| Who is the CEO of LAVA Therapeutics? | LAVA Therapeutics's CEO is Mr. Stephen A. Hurly. |
| Is LAVA Therapeutics publicy listed? | Yes, LAVA Therapeutics is a public company listed on NAS. |
| What is the stock symbol of LAVA Therapeutics? | LAVA Therapeutics trades under LVTX ticker. |
| When did LAVA Therapeutics go public? | LAVA Therapeutics went public in 2021. |
| Who are competitors of LAVA Therapeutics? | Similar companies to LAVA Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of LAVA Therapeutics? | LAVA Therapeutics's current market cap is $30.5M |
| What is the current revenue of LAVA Therapeutics? | LAVA Therapeutics's last 12-month revenue is $8.5M. |
| What is the current EV/Revenue multiple of LAVA Therapeutics? | Current revenue multiple of LAVA Therapeutics is -4.8x. |
| What is the current revenue growth of LAVA Therapeutics? | LAVA Therapeutics revenue growth between 2023 and 2024 was 77%. |
| Is LAVA Therapeutics profitable? | Yes, LAVA Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
